SAM
ALXN

Shell Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Shell Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-8,706
Closed -$1.6M – 1533
2021
Q2 		$1.6M Sell
8,706
-1,108
-11% -$190K 0.03% 413
2021
Q1 		$1.5M Sell
9,814
-1,783
-15% -$276K 0.03% 415
2020
Q4 		$1.81M Buy
11,597
+3,549
+44% +$456K 0.04% 399
2020
Q3 		$921K Buy
8,048
+911
+13% +$98.3K 0.02% 479
2020
Q2 		$801K Sell
7,137
-10,321
-59% -$1.1M 0.02% 502
2020
Q1 		$1.57M Sell
17,458
-1,100
-6% -$108K 0.04% 342
2019
Q4 		$2.01M Sell
18,558
-400
-2% -$42.8K 0.04% 367
2019
Q3 		$1.86M Hold
18,958
– – 0.04% 357
2019
Q2 		$2.48M Sell
18,958
-1,136
-6% -$146K 0.05% 318
2019
Q1 		$2.72M Buy
20,094
+5,677
+39% +$706K 0.06% 305
2018
Q4 		$1.4M Sell
14,417
-1,257
-8% -$149K 0.04% 403
2018
Q3 		$2.18M Sell
15,674
-1,308
-8% -$164K 0.04% 370
2018
Q2 		$2.11M Buy
16,982
+1,769
+12% +$207K 0.04% 389
2018
Q1 		$1.7M Sell
15,213
-11,663
-43% -$1.39M 0.03% 443
2017
Q4 		$3.21M Buy
26,876
+4,336
+19% +$528K 0.06% 303
2017
Q3 		$3.16M Sell
22,540
-3,535
-14% -$480K 0.07% 286
2017
Q2 		$3.17M Sell
26,075
-1,102
-4% -$128K 0.07% 289
2017
Q1 		$3.29M Sell
27,177
-851
-3% -$110K 0.07% 279
2016
Q4 		$3.43M Sell
28,028
-6,730
-19% -$824K 0.08% 267
2016
Q3 		$4.26M Buy
+34,758
New +$4.47M 0.09% 253

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Shell Asset Management's ALXN Position: Q3 2021 in Review

Shell Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 8,706 shares — an estimated $1.6M sold.

Shell Asset Management first reported a position in ALXN in Q3 2016 and held it in 20 quarters. The position peaked at $4.26M in Q3 2016. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Shell Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Shell Asset Management sold 8,706 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1.6M.
  • Shell Asset Management first reported a position in Alexion Pharmaceuticals in Q3 2016 and held it in 20 quarters.
  • Shell Asset Management's Alexion Pharmaceuticals position peaked at $4.26M in Q3 2016.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Shell Asset Management's 13F filing for Q3 2021, filed 4 Nov 2021.